BioLineRx Ltd. (BLRX)

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $19.08 million. The enterprise value is $19.53 million.

Market Cap	19.08M
Enterprise Value	19.53M

Important Dates

The last earnings date was Monday, November 25, 2024, before market open.

Earnings Date	Nov 25, 2024
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 1.20 billion shares outstanding. The number of shares has increased by 23.34% in one year.

Current Share Class	n/a
Shares Outstanding	1.20B
Shares Change (YoY)	+23.34%
Shares Change (QoQ)	+0.16%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.09B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.52, with a Debt / Equity ratio of 3.48.

Current Ratio	1.52
Quick Ratio	1.33
Debt / Equity	3.48
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.56

Financial Efficiency

Return on equity (ROE) is -184.09% and return on invested capital (ROIC) is -53.91%.

Return on Equity (ROE)	-184.09%
Return on Assets (ROA)	-32.96%
Return on Capital (ROIC)	-53.91%
Revenue Per Employee	$278,367
Profits Per Employee	-$252,127
Employee Count	79
Asset Turnover	0.42
Inventory Turnover	2.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.99% in the last 52 weeks. The beta is 0.87, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	-87.99%
50-Day Moving Average	0.37
200-Day Moving Average	0.63
Relative Strength Index (RSI)	26.09
Average Volume (20 Days)	1,723,973

Short Selling Information

Short Interest	921,883
Short Previous Month	1.10M
Short % of Shares Out	1.33%
Short % of Float	n/a
Short Ratio (days to cover)	2.39

Income Statement

In the last 12 months, BioLineRx had revenue of $21.99 million and -$19.92 million in losses. Loss per share was -$0.02.

Revenue	21.99M
Gross Profit	15.13M
Operating Income	-27.85M
Pretax Income	-49.15M
Net Income	-19.92M
EBITDA	-25.49M
EBIT	-27.85M
Loss Per Share	-$0.02

Balance Sheet

The company has $29.17 million in cash and $29.61 million in debt, giving a net cash position of -$441,000 or -$0.00 per share.

Cash & Cash Equivalents	29.17M
Total Debt	29.61M
Net Cash	-441,000
Net Cash Per Share	-$0.00
Equity (Book Value)	8.51M
Book Value Per Share	0.01
Working Capital	12.89M

Cash Flow

In the last 12 months, operating cash flow was -$30.27 million and capital expenditures -$75,000, giving a free cash flow of -$30.35 million.

Operating Cash Flow	-30.27M
Capital Expenditures	-75,000
Free Cash Flow	-30.35M
FCF Per Share	-$0.03

Margins

Gross margin is 68.78%, with operating and profit margins of -126.62% and -90.57%.

Gross Margin	68.78%
Operating Margin	-126.62%
Pretax Margin	-90.57%
Profit Margin	-90.57%
EBITDA Margin	-115.92%
EBIT Margin	-126.62%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.34%
Shareholder Yield	-23.34%
Earnings Yield	-104.40%
FCF Yield	-159.06%

Analyst Forecast

The average price target for BioLineRx is $5.50, which is 2,609.36% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.50
Price Target Difference	2,609.36%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on July 15, 2019. It was a reverse split with a ratio of 0.0666666:1.

Last Split Date	Jul 15, 2019
Split Type	Reverse
Split Ratio	0.0666666:1

Scores

BioLineRx has an Altman Z-Score of -10.48. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.48
Piotroski F-Score	n/a